Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome

Bibliography

• KING H, REWERS M: Global estimatesfor the prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care (1993) 16:157–177.
   PubMed Web of Science ®Google Scholar
• SCHNEDL WJ, LIEBMINGER A, ROLLER R et al.: Hemoglobin variants and determination or glycated hemoglobin (HbAl c). Diabetes Metab. Res. Rev (2001) 17:94–98.
   PubMed Web of Science ®Google Scholar
• REAVEN GM: Syndrome X: 6 years later. Intern. Med. (1994) (Suppl. 736):13–22.
   Google Scholar
• BRINTON EA: Lipid abnormalities in the metabolic syndrome. Curc Diab. Rep. (2003) 3(1):65–72.
   PubMedGoogle Scholar
• MCVEIGH GE, COHN JN: Endothelial dysfunction and the metabolic syndrome. Curc Diab. Rep. (2003) 3(1):87–92.
   PubMedGoogle Scholar
• VIRGIN SE, SCHMITKE JA: Metabolic syndrome. AAOHN (2003) 51(1):28–37.
   PubMedGoogle Scholar
• REAVEN GM: Pathophysiology of insulin resistance in human disease. Physiol Rev (1995) 75(3):473–486.
   PubMed Web of Science ®Google Scholar
• VOSPER H, KHOUDOLI GA, GRAHAM TL et al.: Perwdsome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis. Pharmacol Then (2002) 95(1):47–62.
   PubMed Web of Science ®Google Scholar
• BERGER J, WAGNER JA: Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Diabetes 7echnol. flier. (2002) 4(2):163–174.
   Google Scholar
• ••Well written review of PPARs.
   Google Scholar
• ISSEMANN I, GREEN S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (1990) 347:645–650.
   PubMed Web of Science ®Google Scholar
• DREYER C, KREY G, KELLER H et al: Control of the perwdsomal 13-oxidation pathway by a novel family of nuclear hormone receptors. Cell (1992) 68:879–887.
   PubMed Web of Science ®Google Scholar
• ZHU Y, ALVARES K, QIN H et al: Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver.' Biol. Chem. (1993) 268:26817–26820.
   Web of Science ®Google Scholar
• TONTONOZ P, HUE, GRAVES R et al: mPPARy2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. (1994) 8:1224–1234.
   PubMed Web of Science ®Google Scholar
• KLIEWER SA, FORMAN BA, BLUMBERG B et al.: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Nati Acad. Sci. USA (1994) 91:7355–7359.
   PubMed Web of Science ®Google Scholar
• BERGER J, MOLLER DE: The Mechanism of action of PPARs. Ann. Rev Med. (2002) 53:409–435.
   PubMed Web of Science ®Google Scholar
• ••Detailed overview of PPAR biology.
   Google Scholar
• KLIEWER SA, XU HE, LAMBERT MH et al.: Peroxisome proliferator-activated receptors: from genes to physiology. Rec. Frog. Holm. Res. (2001) 56:239–263.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of PPAR biology andpharmacology.
   Google Scholar
• SEEDORF U, ASSMANN G: The role of PPARa in obesity. Nat. Metab. Cardiovasc. Dis. (2001) 11:189–194.
   PubMed Web of Science ®Google Scholar
• ROSEN ED, SPIEGELMAN BM: PPARy a nuclear receptor of metabolism, differentiation, and cell growth. I Biol. Chem. (2001) 276:37731–37734.
   Web of Science ®Google Scholar
• WILSON TM, BROWN PJ, STERNBACH DD et al.: The PPARs: from orphan receptors to drug discovery. Med. Chem. (2000) 43:527–550.
   Web of Science ®Google Scholar
• ••Excellent review of PPAR biology andsynthetic PPAR ligands.
   Google Scholar
• FORMAN BM, CHEN J, EVANS RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors a and 8. Proc. Nati Acad. Sci. USA (1997) 94:4312–4317.
   PubMed Web of Science ®Google Scholar
• OLIVER WR Jr, SHENK JL, SNAITH JL et al.: A selective peroxisome proliferator-activated receptor 8 agonist promotes reverse cholesterol transport. Proc. Nati Acad. Sci. USA (2001) 98:5306–5311.
   PubMed Web of Science ®Google Scholar
• WANG Y-W, LEE C-H, TIEP S et al.: Perwdsome-proliferator-activated receptor 8 activates fat metabolism to prevent obesity. Cell (2003) 113:159–170.
   PubMed Web of Science ®Google Scholar
• KLIEWER SA, WILSON TM: The nuclear receptor PPARy - bigger than fat. Curc Opin. Genet. Dev. (1998) 8:576–581.
   PubMed Web of Science ®Google Scholar
• ••Well written review of PPAR biology.
   Google Scholar
• WARNER-LAMBERT CO.: Warner-Lambert voluntarily discontinues the sale of Rezulin (2000) (Press release).
   Google Scholar
• ARONOFF S, ROSEBLATT S, BRAITHWAITE S et al: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with Type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care (2000) 23: 1605-1611.
   Google Scholar
• ROSENBLATT S, MISKIN B, GLAZER B et al.: The impact of pioglitazone on glycemic control and atherogenmic dyslipidemia in patients with Type 2 diabetes mellitus. Coron. Artery Dis. (2001) 12:413–423.
   PubMed Web of Science ®Google Scholar
• WAGSTAFF AJ, GOA KL: Rosiglitazone.A review of its use in the management of Type 2 diabetes mellitus. Drugs (2002) 62:1805–1837.
   Google Scholar
• PHILLIPS LS, GRUNBERGER G, MILLER E et al.: Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with Type 2 diabetes. Diabetes Care (2001) 24:308–315.
   PubMed Web of Science ®Google Scholar
• LEBOVITZ HE, DOLE JF, PAT WARDHAN R et al.: Rosiglitazone monotherapy is effective in patients with Type 2 diabetes. j. Clin. Endocrinol Metab. (2001) 86:280–288.
   Google Scholar
• MARTENS FMAC, VISSEREN FLJ, LEMAY J et al.: Metabolic and additional vascular effects of thiazolidinediones. Drugs (2002) 62:1463–1480.
   PubMed Web of Science ®Google Scholar
• UPTON R, WIDDOWSON PS, KADOWAKI S et al.: Improved insulin sensitivity in Zucker and ZDF rats following chronic treatment with novel thiazolidinedione MCC-555. Br: J. Phannacol (1997) 122(Proc. Suppl.):149P.
   Google Scholar
• ISHII S, WASAKI M, OHE T et al: MCC-555: a highly potent thiazolidinedione lacking hematological and cardiac side-effects. Diabetes (1996) 45\(Suppl. 2):141A.
   Google Scholar
• Mitsubishi licenses antidiabetic to J & J. Piranha Japan (1998) 1621:13.
   Google Scholar
• ISHII S, HIKE N, YOSHIDA T: The improving effect of MCC-555, an insulin sensitizer, on glucose tolerance in obese cynomolgus monkeys. Diabetes (1999) 48\(Suppl. 1):A452–A453.
   Google Scholar
• ARAKI K, YACHI M, HAGISAWA Y et al.: Antidiabetic characterization of CS-011: a new thiazolidinedione with potent insulin-sensitizing activity. Diabetes (2000) 49 (Suppl. 1) :A105.
   Google Scholar
• PULASKI JT, DAVIS JA, YUILLE K et al.: The antidiabetic effects of CI-1037/CS011, a new thiazolidinedione. Diabetes (2000) 49\(Suppl. 1):A122.
   Google Scholar
• SANKYO CO. LTD: Drug development pipeline: gemfibrozil, azeinidipine, CS-834, CS-940, MM-801, CS-891, CS-891B, CS-615, CS-747, CS-682, CS-780, CS-011, cadrofloxican, oxybutynin, transdermal, TheraTech. (1999) (Company Communication).
   Google Scholar
• MEDICHERIA S, DEY D, NEOGI P et al.: CLX-0921: A new PPAR-gamma agonist anti-diabetic thiazolidinedione compound. Diabetes (2000) 49\(Suppl. 1):475–P
   Google Scholar
• NESCHEN S, BRUNMAIR B, RODEN M et al.: The thiazolidinedione BM-13.1258 insulin-independently increases muscle glucose oxidation in obese rats. Diabetologia (1998) 41 (Suppl. 1):A186.
   Google Scholar
• BRUNMAIR B, GRAS F, NESCHEN S et al.: Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-y-mediated changes in gene expression. Diabetes (2001) 50:2309–2315.
   PubMed Web of Science ®Google Scholar
• GOWRI MS: Orally active, synthetic anti-diabetic compounds derived from medicinal plants. SMI Conference, Frankfurt am Main, Germany (2002).
   Google Scholar
• ROCHE HOLDING AG. (2001) (Presentation to investors).
   Google Scholar
• NAITOH T, NAKABEPPU H, TAKESHI Y et al.: NIP-221 is a novel and potent thiazolidinedione-based peroxisome proliferator-activated receptor (PPAR)y ligand with long biological half-time. Diabetes (2000) 49\(Suppl. 1):A118.
   Google Scholar
• NAITOH T, KAMON J, YOTSUMOTO T et al.: NIP-223 is a novel and potent thiazolidinedione-based peroxisome proliferator-activated receptor (PPAR)-gamma ligand. Diabetes (2000) 49\(Suppl. 1):481–P
   Google Scholar
• LOHRAY BB, BHUSHAN V, RAO BP et al.: Novel euglycemic and hypolipidemic agents. J. Med. Chem. (1998) 41(10):1619–1630.
   PubMed Web of Science ®Google Scholar
• LOHRAY BB, BHUSHAN V, BHEEMA RP et al: Novel indole containing thiazolidinedione derivatives as potent euglycemic and hypolipidaemic agents. Bioorg. Med. Chem. Lett. (1997) 7(7):785–788.
   Web of Science ®Google Scholar
• ANIMATI F, ARCAMONE F, BIGIONI M et al: Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation. MoL PharmacoL (1996) 50:603–609.
   PubMed Web of Science ®Google Scholar
• BROWN KK, HENKE BR, BLANCHARD SD et al.: A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes (1999) 48:1415–1424.
   PubMed Web of Science ®Google Scholar
• LIU KG, LAMBERT MH, AYSCUE AH et al.: Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight. Bioorg. Med. Chem. Lett. (2001) 11(24):3111–3113.
   PubMed Web of Science ®Google Scholar
• TULARIK, INC.: Tularik begins Phase I clinical trial of T131, a novel insulin sensitizer for the treatment of Type 2 diabetes (2003) (Press release).
   Google Scholar
• IMOTO H, SUGIYAMA Y, KIMURA H et al.: Studies on non-thiazolidinedione antidiabetic agents. 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents. Chem. Pharm. Bull. (2003) 51(2):138–151.
   Google Scholar
• KAO BC, BORDEAUX KG, KHETARPAL V et al.: Synthesis of 5 (2 (4 quinolin 2 yl methoxy)phenoxymethyl)benzyl tetrazole[14-C-tetrazol] - an oral active LTD4 antagonist and pharmacokinetics in rats. 209th American Chemical Society Meeting, Anaheim, CA, USA (1995):MEDI 215 (Abstract).
   Google Scholar
• BROOKS CDW, SUMMERS JB: Modulator of leukotriene biosynthesis and receptor activation. J. Med.Chem. (1996) 39(14):2629–2654.
   PubMed Web of Science ®Google Scholar
• STEVENS JC, FAYER JL, CASSIDY KC:Characterization of 2-[[4- [[2-(1H-tetrazol-5-ylmethyl)phenyl] methoxylmethyliquinoline N-glucuronidation by M vitro and in vivo approaches. Drug Metab. Dispos. (2001) 29(3):289–295.
   PubMed Web of Science ®Google Scholar
• PILL J, NAKAYAMA M, BODKIN NL et al. Lipid modulating and antidiabetic potency of the PPARa activators BM 17.074 and Bezafibrate. PPARs: from Basic Science to Clinical Applications, Florence, Italy (2001):6.
   Google Scholar
• AASUM E, BELKE DD, SEVERSON DL et al.: Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM17.0744, a novel ppar-a activator. Am. Physiol Heart ChM Physiol (2002) 283:H949–H957.
   Google Scholar
• SCHAFER S, BODKIN NL, HANSEN BC et al.: Metabolic alteration induced by K-111, a PPAR activator, in non-human primates. PPARs: Transcriptional Regulators of Metabolism and Metabolic Disease, Keystone, CO, USA (2003):306.
   Google Scholar
• WANG X, BARR RJ, BEAN JS et al.: Synthesis and SAR studies toward the selective PPARa agonist LY518674. ACS 224th National Meeting Boston, USA (2002):MEDI 363 (Abstract).
   Google Scholar
• LEIBOWITZ MD, FIEVET C, HENNUYER N et al: Activation of PPAR S alters lipid metabolism in db/db mice. FEBS Lett. (2000) 473:333–336.
   PubMed Web of Science ®Google Scholar
• MURAKAMI K, TOBE K, IDE T et al: A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes (1998) 47:1841–1847.
   PubMed Web of Science ®Google Scholar
• MURAKAMI K, TSUNODA M, OHASHI M et al.: Amelioration by KRP-297, a new thiazolidinedione, of impaired glucose uptake in skeletal muscle from obese insulin-resistant animals. Metabolism (1999) 48(11) :1450–1454.
   PubMed Web of Science ®Google Scholar
• SORBERA LA, LEESON PA, MARTIN L et al.: Farglitazar. GI-262570. Drugs Future (2001) 26:354–363.
   Google Scholar
• O'CONNOR SEMMES R, MYDLOW P, WALKER A et al: GI 262570, A PPAR-gamma agonist, maintains metabolic improvements throughout 24 hour profile in Type 2 diabetic patients. Diabetes (2000) (Suppl. 1) :A119 (Press release).
   Google Scholar
• EDWARDS RC, KLER L, MCNEIL SJ et al: GI 262570, a tyrosine-based PPAR-gamma agonist, reduces triglycerides and increases HDL-C concentrations in patients with Type 2 diabetes mellitus when combined with glibenclamide treatment. Diabetes (2000) 49\(Suppl. 1):A104–A105.
   Google Scholar
• WILLSON TM, COLLINS JL, HENKLE BR et al: PPAR agonists for metabolic diseases. 220th ACS Meeting, Washington, DC (2000):MEDI 197.
   Google Scholar
• CRONET P, PETERSEN JFW, FOLMER R et al.: Structure of the PPARa and -y ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure (2001) 9:699–706.
   PubMed Web of Science ®Google Scholar
• OAKES N, KJELLSTEDT A, THAL P et at AZ 242, a novel PPAR[alpha]/ [gamma] agonist, enhances the severely impaired metabolic flexibility and insulin action in skeletal muscle of obese Zucker rats. Diabetes (2002) 51 (Suppl. 2) :A110.
   Google Scholar
• ROSENGREN B, CARINA H, EVA HC et at AZ 242, a novel PPAR[alpha]/ [gamma] agonist, improves the hdl-mediated efflux of cholesterol from differentiated, triglyceride-overloaded THP-1 monocytes. Diabetes (2002) 51\(Suppl. 2):A143.
   Google Scholar
• LOHRAY BB, LOHRAY VB, BAJJI AC et al.: 03-[4-[24Phenoxazin-10-y6ethoxy]pheny11-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. I Med. Chem. (2001) 44:2675–2678.
   PubMed Web of Science ®Google Scholar
• CHENG PT, CHANDRASENA G, CHEN S et al: BMS-298585 is a novel, uniquely balanced dual activator of peroxisome proliferator activated receptors (PPAR) alpha and gamma, with an excellent ADME profile. Diabetes (2002) 51\(Suppl. 2):A94.
   Google Scholar
• NOVO NORDISK A/S: Novo Nordisk suspends the clinical development of Ragaglitazar. (2002) (Press release).
   Google Scholar
• REIFEL-MILLER A, WARSHAWSKY A, ARDECKY R et al: LY519818: a novel non-TZD, PPARy-dominant agonist with improved insulin sensitization and unique co-factor recruitment and response element activation profiles. Diabetes (2003) 52\(Suppl. 1):A143.
   Google Scholar
• ETGEN GJ, BRODERICK CL, OLDHAM BA et al.: LY510929: a novel highly potent PPARa,y dual agonist for the treatment of Type 2 diabetes and associated dyslipidemia. Diabetes (2003) 52\(Suppl. 1):A141.
   Google Scholar
• ETGEN GJ, OLDHAM BA, JOHNSON WT et al.: A tailored therapy for the metabolic syndrome. The dual peroxisome proliferator-activated receptor-a/y agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes (2002) 51:1083–1087.
   Google Scholar
• ETGEN GJ, MANTLO N: PPAR ligands for metabolic disorders. Carr: Top. Med. Chem. (2003) (In press).
   Google Scholar
• LIU KG, LAMBERT MH, LEESNITZER LM et al.: Identification of a series of PPARy/8 dual agonists via solid-phase parallel synthesis. Bioorg. Med. Chem. Lett. (2001) 11:2959–2962.
   PubMed Web of Science ®Google Scholar
• OLIVER WR, RAFFERTY S, BODKIN NL et al.: Simultaneous activation of the three peroxisome proliferator-activated receptors (PPAR) subtypes with a PPARpanTM agonist improves insulin resistance and symptoms associated with metabolic syndrome in obese hyperglycemic rhesus monkeys. Diabetes (2003) 52 (Suppl. 1):A129.
   Google Scholar
• BERGER J, LEIBOWITZ MD, DOEBBER TW et al.: Novel peroxisome proliferator-activated receptor (PPAR) y and PPAR S ligands produce distinct biological effects. J. Biol. Chem. (1999) 274:6718–6725.
   PubMed Web of Science ®Google Scholar
• MCDONNELL D, CLEMM D, HERMANN T et al.: Analysis of estrogen receptor function M vitro reveals three distinct classes of antiestrogens. MoL Endocrinol (1995) 9(6):659–669.
   PubMed Web of Science ®Google Scholar
• OBERFIELD JL, COLLINS JL, HOLMES CP et al.: A peroxisome proliferator-activated receptor y ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. USA (1999) 96(11):6102–6106.
   PubMed Web of Science ®Google Scholar
• ROCCHI S, PICARD F, VAMECQ J et al.: A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. MM. Cell (2001) 8(4)737–747.
   Google Scholar
• BERGER JP, PETRO AE, MACNAUL KL et al.: Distinct properties and advantages of a novel PPARgamma selective modulator. Endocrinol (2003) 17(4):662–676.
   Web of Science ®Google Scholar
• ELBRECHT A, CHEN Y, ADAMS A: L-764406 is a partial agonist of human peroxisome proliferator-activated receptor y. Biol. Chem. (1999) 274(12):7913–7922.
   Web of Science ®Google Scholar
• KUROSAKI E, NAKANO R, SHIMAYA A et al.: Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor y and its transactivation. Biochem. Pharmacol (2003) 65:795–805.
   PubMed Web of Science ®Google Scholar
• SHIMAYA A, KUROSAKI E, NAKANO R et al.: The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. Metabolism (2000) 49(3):411–417.
   PubMed Web of Science ®Google Scholar
• DRAGOMIR K, IONESCU- TRGOVISTE CI, ROSENTHAL A et al.: Balaglitazone, a new thiazolidinedione, improves glucose and lipid control in patients with Type 2 diabetes. Diabetes (2003) 52\(Suppl. 1):530P.
   Google Scholar
• CHAKRABARTI R, VIKRAMADITHYAN R, MISRA P et al.: Balaglitazone, a quinazalone analogue of thiazolidinedione shows excellent antidiabetic and hypolipidemic potential with less adipogenic activity. Diabetes (2003) 52\(Suppl. 1):601P.
   Google Scholar
• WULFF E, PEDERSEN K, SAUERBERG P: Balaglitazone a new partial PPARy agonist has a better cardio vascular safety profile and glycemic control compared with the full PPARy agonist rosiglitazone. Diabetes (2003) 52\(Suppl. 1):594P
   Google Scholar
• REGINATO MJ, BAILEY ST, KRAKOW SL et al.: A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J. Biol. Chem. (1998) 273(49):32679–32684.
   PubMed Web of Science ®Google Scholar
• CAMP H, OU L, WISE SC et al.: Differential activation of peroxisome proliferator-activated receptor-y by troglitazone and rosiglitazone. Diabetes (2000) 49(4):539–547.
   PubMed Web of Science ®Google Scholar
• FONSECA V, FOYT HL, SHEN K et al: Long-term effects of troglitazone: open-label extension studies in Type 2 diabetic patients. Diabetes Care (2000) 23 (3):354–359.
   PubMed Web of Science ®Google Scholar
• HORIKOSHI H, HASHIMOTO T, FUJI WARA T: Troglitazone and emerging glitazones: new avenues for potential therapeutic benefits beyond glycemic control. Frog. Drug Res. (2000) 54:191–212.
   PubMedGoogle Scholar
• SUNAYAMA S, WATANABE Y, OHMURA H et al.: Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis (1999) 146 (1) :187–193.
   PubMed Web of Science ®Google Scholar
• KAWAI T, TAKEI I, OGUMA Y et al.: Effects of troglitazone on fat distribution in the treatment of male Type 2 diabetes. Metabolism (1999) 48 (9) :1102–1107.
   PubMed Web of Science ®Google Scholar
• CHEAH JS: Management of obesity in non-insulin-dependent diabetes mellitus. Asia Padficj Clin. Nutrition (1998) 7(3/4):282–286.
   Google Scholar
• RIEUSSET J, TOURI F, MICHALIK L et al.: A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity antidiabetic activity. MoL Endocrinol (2002) 16(11):2628–2644.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE R, HOENER PA, JOW L et al.: A selective peroxisome proliferator-activated receptor y (PPARy) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. MM. Endocrinol (2000) 14(9):1425–1433.
   PubMed Web of Science ®Google Scholar
• AL-SHAMMA H, CARTER B, CHEN Q et al.: Inhibitor of PPARgamma activity displays anti-diabetic and anti-dyslipidemic action in vivo. Diabetes (2001) 50\(Suppl. 2):A105.
   Google Scholar
• LALA DS, MUKHERJEE R, SCHULMAN IG et al.: Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature (1996) 383(6599):450–453.
   PubMed Web of Science ®Google Scholar
• MICHELLYS PY, ARDECKY RJ, CHEN JH et al.: Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta- 2,4,6-trienoic acid retinoid X receptor modulators are active in models of Type 2 diabetes. J. Med. Chen]. (2003) 46(13):2683–2696.
   PubMed Web of Science ®Google Scholar
• REIFEL-MILLER A, ARDECKY RJ, BOEHM MF et al: Selective RXR modulators: improvements over RXR agonists for the treatment of Type 2 diabetes. In: PPARs: Transcriptional Regulators of Metabolism and Metabolic Disease, Keystone, CO, USA (2003):141.
   Google Scholar